Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_E79AD2CE350B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Production externe
Title
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
Journal
Journal of Crohn's and Colitis
Author(s)
Danese S., Fiorino G., Michetti P.
ISSN
1876-4479 (Electronic)
ISSN-L
1873-9946
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
8
Number
11
Pages
1548-1550
Language
english
Abstract
BACKGROUND: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.
METHODS: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
Keywords
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Antibodies, Monoclonal/therapeutic use, Attitude of Health Personnel, Biosimilar Pharmaceuticals/therapeutic use, Colitis, Ulcerative/drug therapy, Crohn Disease/drug therapy, Drug Approval, Drug Substitution, Europe, Gastroenterology, Health Care Surveys, Health Knowledge, Attitudes, Practice, Humans
DOI
10.1016/j.crohns.2014.06.007
Pubmed
25008477
Open Access
Yes
Create date
25/11/2015 16:10
Last modification date
20/08/2019 16:10
Usage data